JPWO2023086480A5 - - Google Patents

Info

Publication number
JPWO2023086480A5
JPWO2023086480A5 JP2024527417A JP2024527417A JPWO2023086480A5 JP WO2023086480 A5 JPWO2023086480 A5 JP WO2023086480A5 JP 2024527417 A JP2024527417 A JP 2024527417A JP 2024527417 A JP2024527417 A JP 2024527417A JP WO2023086480 A5 JPWO2023086480 A5 JP WO2023086480A5
Authority
JP
Japan
Prior art keywords
hla
optionally
magea1
peptide
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024527417A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024546018A5 (https=
JP2024546018A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/049556 external-priority patent/WO2023086480A2/en
Publication of JP2024546018A publication Critical patent/JP2024546018A/ja
Publication of JPWO2023086480A5 publication Critical patent/JPWO2023086480A5/ja
Publication of JP2024546018A5 publication Critical patent/JP2024546018A5/ja
Pending legal-status Critical Current

Links

JP2024527417A 2021-11-10 2022-11-10 Ｍａｇｅａ１免疫原性ペプチド、ｍａｇｅａ１免疫原性ペプチドを認識する結合性タンパク質、及びその使用 Pending JP2024546018A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163277924P 2021-11-10 2021-11-10
US63/277,924 2021-11-10
US202263317337P 2022-03-07 2022-03-07
US63/317,337 2022-03-07
US202263342415P 2022-05-16 2022-05-16
US63/342,415 2022-05-16
PCT/US2022/049556 WO2023086480A2 (en) 2021-11-10 2022-11-10 Magea1 immunogenic peptides, binding proteins recognizing magea1 immunogenic peptides, and uses thereof

Publications (3)

Publication Number Publication Date
JP2024546018A JP2024546018A (ja) 2024-12-17
JPWO2023086480A5 true JPWO2023086480A5 (https=) 2025-11-18
JP2024546018A5 JP2024546018A5 (https=) 2025-11-18

Family

ID=86336428

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024527417A Pending JP2024546018A (ja) 2021-11-10 2022-11-10 Ｍａｇｅａ１免疫原性ペプチド、ｍａｇｅａ１免疫原性ペプチドを認識する結合性タンパク質、及びその使用

Country Status (11)

Country Link
US (1) US20230270832A1 (https=)
EP (1) EP4430067A2 (https=)
JP (1) JP2024546018A (https=)
KR (1) KR20240112285A (https=)
AU (2) AU2022268347C1 (https=)
CA (1) CA3237903A1 (https=)
CO (1) CO2024007212A2 (https=)
IL (1) IL312744A (https=)
MX (1) MX2024005746A (https=)
TW (1) TW202340224A (https=)
WO (1) WO2023086480A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116716327B (zh) * 2023-08-04 2023-10-20 科士华(南京)生物技术有限公司 一种构建tcr载体的方法
TW202523702A (zh) * 2023-10-27 2025-06-16 美商帝斯肯醫療公司 Magea1免疫原性肽、識別magea1免疫原性肽之結合蛋白及其用途
TWI871128B (zh) * 2023-12-08 2025-01-21 陳乃銘 可準確提供循環腫瘤細胞（ｃｔｃ）所需藥物種類之方法
WO2025217037A2 (en) * 2024-04-08 2025-10-16 Tscan Therapeutics, Inc. Use of binding proteins for treatment of solid tumors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9340577B2 (en) * 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
JPH09502086A (ja) * 1993-08-06 1997-03-04 サイテル コーポレイション 完全ｍａｇｅ１遺伝子のクローニング及び特性決定
WO2005115447A2 (en) * 2004-05-25 2005-12-08 The Trustees Of The University Of Pennsylvania Human anti-cancer immunotherapy
WO2010037395A2 (en) * 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
AU2017252192C1 (en) * 2016-04-19 2023-06-08 Imcyse Sa Novel immunogenic CD1d binding peptides
CN113795586B (zh) * 2019-03-25 2026-03-27 大学健康网络 T细胞受体及其使用方法
WO2021119545A1 (en) * 2019-12-11 2021-06-17 Gritstone Bio, Inc. Durable vaccination
US11464842B1 (en) * 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization

Similar Documents

Publication Publication Date Title
JP7270001B2 (ja) Ｍｈｃクラスｉｉ拘束性ｍａｇｅ－ａ３を認識するｔ細胞受容体
CN112979783B (zh) 获得肿瘤特异性t细胞受体的方法
EP3241561B1 (en) Conjugated antibody or bispecific t-cell engager which selectively binds either tcr beta constant region 1 (trbc1) or trbc2
EP4286407B1 (en) Anti-mutated kras t cell receptors
JP2023534808A (ja) 養子細胞療法のための標的共刺激を提供する受容体
US12275786B2 (en) Anti-thyroglobulin t cell receptors
US10987413B2 (en) MHC-independent tumor-associated antigens
CN113195526B (zh) 针对过继性t细胞疗法中的突变myd88l265p蛋白表位的特异性t细胞受体
JPH08504170A (ja) 進行性免疫抑制症患者の評価と治療
US20210061876A1 (en) T cell receptors for tumor specific proteasome splice variants and uses thereof
Hill et al. Early‐onset myasthenia gravis: A recurring T‐cell epitope in the adult‐specific acetylcholine receptor ε subunit presented by the susceptibility allele HLA‐DR52a
TW201502138A (zh) 對於ｔｈ１細胞之ｉｍｐ－３抗原決定位胜肽及含此之疫苗
JPWO2023086480A5 (https=)
Nakatsugawa et al. CD4+ and CD8+ TCRβ repertoires possess different potentials to generate extraordinarily high-avidity T cells
JPWO2022221479A5 (https=)
JP2025518203A (ja) Ｍａｇｅ－ａ１特異的ｔｃｒ及びその用途
Infante et al. Myasthenia gravis and its animal model: T cell receptor expression in an antibody mediated autoimmune disease
JPWO2022221478A5 (https=)
JPWO2022099100A5 (https=)
EP4223782A1 (en) Novel t cell receptors and immune therapy using the same for the treatment of cancer
JP2007097580A (ja) Ｔ細胞レセプターβ鎖遺伝子
Hess et al. Functionally divergent T lymphocyte responses induced by modification of a self-peptide from a tumor-associated antigen
Wei Engineering HLA-I molecules for improved anti-tumor T cell response for cancer immunotherapy
JPWO2022104002A5 (https=)
AU2024374117A1 (en) Antigen-recognizing construct capable of binding to a frame peptide and a t cell receptor